Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Use of an adult rat retinal explant model for screening of potential retinal ganglion cell neuroprotective therapies.

Tytuł:
Use of an adult rat retinal explant model for screening of potential retinal ganglion cell neuroprotective therapies.
Autorzy:
Bull ND; Cambridge Centre for Brain Repair, University of Cambridge, United Kingdom.
Johnson TV
Welsapar G
DeKorver NW
Tomarev SI
Martin KR
Źródło:
Investigative ophthalmology & visual science [Invest Ophthalmol Vis Sci] 2011 May 17; Vol. 52 (6), pp. 3309-20. Date of Electronic Publication: 2011 May 17.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Publication: Brookline Ma : Association For Research In Vision And Ophthalmology (Arvo)
Original Publication: St. Louis, Mosby.
MeSH Terms:
Disease Models, Animal*
Neuroprotective Agents/*pharmacology
Ocular Hypertension/*prevention & control
Optic Nerve Diseases/*prevention & control
Retinal Ganglion Cells/*cytology
Amino Acid Chloromethyl Ketones/pharmacology ; Animals ; Apoptosis/drug effects ; Brain-Derived Neurotrophic Factor/pharmacology ; Caspase Inhibitors ; Cell Survival/drug effects ; Cells, Cultured ; Coculture Techniques ; Colforsin/pharmacology ; Drug Evaluation, Preclinical ; Male ; Mesenchymal Stem Cells/cytology ; Nerve Crush ; Optic Nerve ; Organ Culture Techniques ; Rats ; Rats, Sprague-Dawley ; Retinal Ganglion Cells/physiology ; Stem Cell Transplantation
References:
Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4515-22. (PMID: 18566471)
Prog Neurobiol. 2009 May;88(1):64-75. (PMID: 19428962)
Arch Ophthalmol. 2009 Apr;127(4):402-6. (PMID: 19365015)
Mol Vis. 2008 Aug 31;14:1600-13. (PMID: 18769561)
Eur J Ophthalmol. 2009 Nov-Dec;19(6):963-70. (PMID: 19882581)
J Neurochem. 2008 Aug;106(4):1876-87. (PMID: 18624919)
Invest Ophthalmol Vis Sci. 2002 Aug;43(8):2666-76. (PMID: 12147601)
Brain Res. 1986 Oct 1;384(1):199-203. (PMID: 3098354)
Invest Ophthalmol Vis Sci. 2007 Mar;48(3):1410-5. (PMID: 17325190)
Invest Ophthalmol Vis Sci. 2010 Apr;51(4):2051-9. (PMID: 19933193)
Neurobiol Dis. 2006 Feb;21(2):421-30. (PMID: 16168661)
Cell Mol Neurobiol. 2008 Sep;28(6):833-45. (PMID: 18236013)
Curr Eye Res. 2007 Nov;32(11):991-7. (PMID: 18027175)
Invest Ophthalmol Vis Sci. 2008 Aug;49(8):3503-12. (PMID: 18408186)
Surv Ophthalmol. 2003 Apr;48 Suppl 1:S47-51. (PMID: 12852434)
Glia. 2006 Apr 1;53(5):467-76. (PMID: 16355371)
Methods. 2002 Dec;28(4):439-47. (PMID: 12507462)
J Neurotrauma. 2008 Feb;25(2):130-9. (PMID: 18260796)
J Neurosci Methods. 2007 Jan 15;159(1):35-42. (PMID: 16876874)
Exp Eye Res. 2009 Mar;88(3):535-41. (PMID: 19084521)
Prog Retin Eye Res. 2001 Mar;20(2):175-208. (PMID: 11173251)
J Neurosci. 2008 Jan 9;28(2):548-61. (PMID: 18184797)
Invest Ophthalmol Vis Sci. 2010 Mar;51(3):1789-99. (PMID: 19850827)
Mol Cell Neurosci. 2009 Dec;42(4):427-37. (PMID: 19782753)
Invest Ophthalmol Vis Sci. 2010 Feb;51(2):960-70. (PMID: 19850833)
Exp Eye Res. 2010 Jul;91(1):48-53. (PMID: 20394744)
Graefes Arch Clin Exp Ophthalmol. 2001 Jul;239(7):522-30. (PMID: 11521697)
Exp Eye Res. 2006 Nov;83(5):1108-17. (PMID: 16839545)
Exp Eye Res. 2007 May;84(5):858-67. (PMID: 17343850)
J Pharmacol Exp Ther. 2008 Oct;327(1):130-6. (PMID: 18593956)
Neurosci Lett. 2008 Dec 19;448(1):166-9. (PMID: 18938217)
J Comp Neurol. 2007 Jul 1;503(1):182-97. (PMID: 17480014)
Invest Ophthalmol Vis Sci. 2010 Jul;51(7):3629-38. (PMID: 20164447)
J Neurobiol. 2004 Feb 15;58(3):341-54. (PMID: 14750147)
Exp Eye Res. 2007 Sep;85(3):406-12. (PMID: 17678894)
J Ocul Pharmacol Ther. 2005 Jun;21(3):175-81. (PMID: 15969634)
J Neurochem. 2007 Apr;101(1):77-86. (PMID: 17241114)
J Neuropathol Exp Neurol. 2010 Mar;69(3):272-80. (PMID: 20142763)
Invest Ophthalmol Vis Sci. 2002 Feb;43(2):402-10. (PMID: 11818384)
Neuron. 1998 Oct;21(4):681-93. (PMID: 9808456)
Prog Retin Eye Res. 2010 Jan;29(1):79-93. (PMID: 19733652)
Neuron. 1999 Jun;23(2):285-95. (PMID: 10399935)
Invest Ophthalmol Vis Sci. 2009 Dec;50(12):5800-4. (PMID: 19608537)
Eye (Lond). 2007 Dec;21 Suppl 1:S11-4. (PMID: 18157171)
Invest Ophthalmol Vis Sci. 2008 Nov;49(11):4971-81. (PMID: 18566458)
J Neurosci. 2008 Mar 12;28(11):2735-44. (PMID: 18337403)
Exp Eye Res. 2009 Dec;89(6):921-33. (PMID: 19682984)
Neurosci Lett. 2002 Dec 6;334(1):33-6. (PMID: 12431769)
Invest Ophthalmol Vis Sci. 2005 Sep;46(9):3188-96. (PMID: 16123418)
Exp Eye Res. 2009 Apr;88(4):808-15. (PMID: 19217904)
Development. 1995 Nov;121(11):3637-50. (PMID: 8582277)
Brain Res. 2008 Jan 10;1188:35-43. (PMID: 18053973)
Graefes Arch Clin Exp Ophthalmol. 2009 Oct;247(10):1353-60. (PMID: 19551401)
Exp Eye Res. 2011 Aug;93(2):196-203. (PMID: 20685205)
Invest Ophthalmol Vis Sci. 2009 Sep;50(9):4267-72. (PMID: 19443730)
Exp Eye Res. 2005 Nov;81(5):551-60. (PMID: 15913606)
Neurosci Res. 2004 Nov;50(3):299-306. (PMID: 15488293)
Curr Eye Res. 2006 Mar;31(3):265-71. (PMID: 16531284)
Eur J Neurosci. 2008 Sep;28(6):1166-79. (PMID: 18783366)
Invest Ophthalmol Vis Sci. 2008 May;49(5):1940-5. (PMID: 18436826)
J Mol Neurosci. 2010 Mar;40(3):360-6. (PMID: 20107925)
Exp Neurol. 1998 Sep;153(1):1-7. (PMID: 9743562)
Graefes Arch Clin Exp Ophthalmol. 2006 Aug;244(8):1003-9. (PMID: 16411104)
Exp Eye Res. 2000 Aug;71(2):167-71. (PMID: 10930321)
Invest Ophthalmol Vis Sci. 2000 Oct;41(11):3460-6. (PMID: 11006239)
Expert Opin Investig Drugs. 2001 Oct;10(10):1847-53. (PMID: 11772290)
Grant Information:
G0800784 United Kingdom MRC_ Medical Research Council; T32 GM007309 United States GM NIGMS NIH HHS; T32-GM007309 United States GM NIGMS NIH HHS
Substance Nomenclature:
0 (Amino Acid Chloromethyl Ketones)
0 (Brain-Derived Neurotrophic Factor)
0 (Caspase Inhibitors)
0 (Neuroprotective Agents)
0 (benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone)
1F7A44V6OU (Colforsin)
Entry Date(s):
Date Created: 20110225 Date Completed: 20110728 Latest Revision: 20211020
Update Code:
20240104
PubMed Central ID:
PMC3109030
DOI:
10.1167/iovs.10-6873
PMID:
21345987
Czasopismo naukowe
PURPOSE. To validate an established adult organotypic retinal explant culture system for use as an efficient medium-throughput screening tool to investigate novel retinal ganglion cell (RGC) neuroprotective therapies. METHODS. Optimal culture conditions for detecting RGC neuroprotection in rat retinal explants were identified. Retinal explants were treated with various recognized, or purported, neuroprotective agents and cultured for either 4 or 7 days ex vivo. The number of cells surviving in the RGC layer (RGCL) was quantified using histologic and immunohistochemical techniques, and statistical analyses were applied to detect neuroprotective effects. RESULTS. The ability to replicate previously reported in vivo RGC neuroprotection in retinal explants was verified by demonstrating that caspase inhibition, brain-derived neurotrophic factor treatment, and stem cell transplantation all reduced RGCL cell loss in this model. Further screening of potential neuroprotective pharmacologic agents demonstrated that betaxolol, losartan, tafluprost, and simvastatin all alleviated RGCL cell loss in retinal explants, supporting previous reports. However, treatment with brimonidine did not protect RGCL neurons from death in retinal explant cultures. Explants cultured for 4 days ex vivo proved most sensitive for detecting neuroprotection. CONCLUSIONS. The current adult rat retinal explant culture model offers advantages over other models for screening potential neuroprotective drugs, including maintenance of neurons in situ, control of environmental conditions, and dissociation from other factors such as intraocular pressure. Verification that neuroprotection by previously identified RGC-protective therapies could be replicated in adult retinal explant cultures suggests that this model could be used for efficient medium-throughput screening of novel neuroprotective therapies for retinal neurodegenerative disease.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies